Pharmacokinetics (PK) and toxicokinetics (TK) are critical components of drug development, providing quantitative data on the absorption, distribution, metabolism, and excretion (ADME) of compounds, as well as their concentration–time profiles related to toxic effects. Understanding PK and TK helps optimize dosing regimens, predict human responses, and assess safety margins. Pharmacokinetic studies focus on characterizing drug…
The pursuit of alternatives to animal testing in toxicology has gained significant momentum, driven by ethical considerations, regulatory encouragement, and technological advancements. In vitro methods provide controlled, reproducible platforms to evaluate toxicity while reducing animal use, costs, and study durations. Cell-based assays using primary cells, immortalized cell lines, or stem cell–derived differentiated cells allow assessment…
Biomarkers have become indispensable tools in preclinical toxicology, serving as measurable indicators that reflect biological processes, pharmacologic responses, or toxic effects induced by investigational compounds. Their application spans early drug development to regulatory submissions, enhancing the sensitivity, specificity, and mechanistic understanding of toxicity assessments. In preclinical settings, biomarkers are broadly categorized into exposure biomarkers, effect…
RNA-based therapeutics, including siRNA, antisense oligonucleotides (ASOs), and mRNA vaccines, offer precise modulation of gene expression but also present unique challenges related to off-target effects. These unintended interactions can lead to toxicity, immune activation, or altered expression of non-target genes, complicating preclinical safety assessments. In vitro screening using transcriptomic and proteomic profiling helps identify off-target…
Omics technologies—encompassing genomics, transcriptomics, proteomics, metabolomics, and epigenomics—have transformed toxicology by enabling comprehensive molecular profiling of biological responses to chemical or pharmaceutical exposures. These high-throughput platforms facilitate mechanism-based toxicology by identifying early molecular signatures of toxicity, elucidating affected biological pathways, and uncovering potential biomarkers for safety assessment. Transcriptomics, especially through RNA sequencing (RNA-seq), allows for…
One of the most enduring complexities in preclinical drug development is the limited translational accuracy of animal models in predicting human toxicity. While regulatory agencies require toxicology studies in at least one rodent and one non-rodent species before clinical trials, interspecies differences in physiology, metabolism, immune response, and gene expression frequently lead to discrepancies between…
Immunotoxicity refers to any adverse effect on the structure or function of the immune system induced by exposure to chemical substances, biologics, or therapeutic agents. As immunomodulatory drugs, cell-based therapies, and biologics continue to gain momentum in clinical development, evaluating their impact on immune function has become a central aspect of preclinical safety assessment. In…
Designing toxicology studies that comply with Good Laboratory Practice (GLP) regulations is essential for advancing a drug candidate into clinical trials under an Investigational New Drug (IND) application. GLP compliance ensures data integrity, reproducibility, and regulatory acceptance by governing bodies such as the FDA, EMA, and OECD member states. A GLP-compliant toxicology study begins with…
Toxicogenomics combines toxicology with genomics to study how gene expression changes in response to chemical exposures. By profiling global transcriptional changes following treatment with investigational compounds, toxicogenomics offers insight into the molecular mechanisms underlying toxicity. This approach enhances early risk assessment by identifying biomarkers and adverse outcome pathways before overt toxic effects are observed. In…
Understanding the interplay between pharmacokinetics (PK) and pharmacodynamics (PD) is central to evaluating the safety and efficacy of drug candidates in preclinical studies. PK describes how a compound is absorbed, distributed, metabolized, and excreted (ADME) in a biological system, while PD refers to the biochemical and physiological effects of the compound and its mechanism of…